PIR International was thrilled to partner with Maxion Therapeutics on the appointment of Helen Timmis as VP of Clinical Development.
Maxion Therapeutics (Maxion) is developing a pipeline of potentially first and best-in-class protein therapeutics using its proprietary KnotBody® technology. KnotBody® therapeutics solve a key problem in industry making ion channel and GPCR targets tractable for biologics. Maxion is projected to have the only biologic targeting an ion channel to enter the clinic this year.
Following a thorough evaluation and selection process, Maxion’s ELT appointed Helen Timmis as VP of Clinical Development. Helen brings over 18 years of experience in industry and academia within early clinical research and development, with deep expertise in inflammatory and fibrosis indications. Helen most recently resided as Chief Medical Officer at RedX Pharma, where she oversaw all strategic and operational clinical activities across the business, and was formerly Senior Medical Director at Galapagos, where she led early clinical development across Galapagos’ inflammatory and immune-mediated disease programmes internationally.
Helen’s strong clinical and translational background will play an instrumental role as Maxion Therapeutics advance MAX001 for autoimmune diseases into first-in-human studies later this year and significantly expands their clinical development capabilities. MAX001 has pipeline in a product potential and is projected to be the only biologic targeting an ion channel in the clinic in 2026.
Stefan Härtle, Chief Development Officer of Maxion Therapeutics, said: “The team at PIR International demonstrated exceptional insight and commitment throughout the process. Sally and Stuart took the time to understand our culture and priorities, which resulted in a perfect match for our needs. We’re thrilled to have Helen join us to strengthen our clinical team and to help us advance our lead programme MAX001 and other KnotBody® therapeutics to patients.”
Helen Timmis, VP of Clinical Development at Maxion Therapeutics, commented: “Any recruiter can match a person to a role based on skill set. The uniqueness of the team at PIR International is their thoughtfulness in taking time to understand me as a person and the company’s needs and culture. Sally and Stuart were a pleasure to work with and made the entire process smooth and straightforward with a clear focus on ‘the right fit’. I’m excited to join the team and look forward to supporting Maxion as they move into the clinic.”